LAG3 and cancer: Immune checkpoint inhibitors (ICIs), as vigorous weapons against cancer cells, have revolutionized clinical immunotherapy approaches by targeting specific receptors on immune cells such as PD-1, cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), TIM3, and lymphocyte activation gene 3 (LAG-3) [434, 435].